TMCnet - World's Largest Communications and Technology Community



Research and Markets: Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
[April 15, 2014]

Research and Markets: Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering.

Twinrix [Hepatitis A (Inactivated) & Hepatitis B (Recombinant) Vaccine] is GSK's bivalent combination vaccine that protects children, adolescents, and adults against disease caused by HAV and acute and chronic infections caused by all known strains of HBV. Twinrix contains the antigenic components used in GSK's Havrix (formalin-inactivated HAV) and GSK's Engerix-B (yeast-derived recombinant HBsAg) vaccines (Engerix-B package insert, 2013 Havrix package insert, 2012).


  • Overview of Hepatitis B disease, includin epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Twinrix including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Twinrix for top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Canada.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Twinrix performance
  • Obtain sales forecast for Twinrix from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, UK and Canada).

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Overview

3.2 Etiology and Pathophysiology

3.3 Symptoms

3.4 Prognosis (News - Alert)

4 Vaccination Recommendations and Coverage Rates

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Twinrix

6.1 Overview

6.2 Immunogenicity

6.3 Safety

6.4 SWOT Analysis

6.5 Forecast

7 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy